Login / Signup

Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.

Michaël H MeelMark Cornelis de GooijerDennis S MetselaarA Charlotte P SewingKenn ZwaanPiotr WaraneckiMarjolein BreurLevi C M BuilTonny LagerweijLaurine E WedekindJos W R TwiskJan KosterRintaro HashizumeEric H RaabeÁngel Montero CarcabosoMarianna BugianiTimothy N PhoenixOlaf van TellingenDannis G van VuurdenGertjan J L KaspersEsther Hulleman
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.
Keyphrases
  • bone marrow
  • mesenchymal stem cells
  • tyrosine kinase
  • induced apoptosis
  • stem cells
  • cell cycle arrest
  • current status
  • cancer therapy
  • cell proliferation
  • pain management
  • drug delivery
  • umbilical cord
  • histone deacetylase